Moderna’s tailored COVID-19 vaccine that targets Omicron XBB.1.5 accepted by MHRA



An tailored COVID-19 vaccine from Moderna (Spikevax) that targets the Omicron XBB 1.5 subvariant, has right now been approved by the Medicines and Healthcare merchandise Regulatory Company (MHRA) after it was discovered to satisfy the UK regulator’s requirements of security, high quality and effectiveness.

The vaccine has been accepted to be used in people from 6 months of age.

The tailored vaccine works in the identical means as the unique vaccine by inflicting the immune system (the physique’s pure defenses) to supply antibodies and blood cells that work towards the virus, so giving safety towards COVID-19. All accepted tailored COVID-19 vaccines assist to enhance the safety obtained from earlier doses of the vaccine and assist give longer-term safety towards getting severely in poor health from COVID-19.

Additional data:

  • This new line extension was accepted by way of the Nationwide licensing route. This advertising authorisation has been endorsed by the federal government’s unbiased Fee on Human Medicines after evaluation of the information submitted on the standard, security and effectiveness of the vaccine.
  • Extra data might be discovered within the vaccine determination web page on mhra.gov.uk
  • The Public Evaluation Report shall be printed shortly.

Leave a Reply

Your email address will not be published. Required fields are marked *